Treatment of type 2 diabetes

被引:5
|
作者
Meier, J. J. [1 ]
机构
[1] Klinikum Ruhr Univ Bochum, Univ Klinikum St Josef Hosp, Abt Diabetol, Gudrunstr 56, D-44791 Bochum, Germany
来源
INTERNIST | 2016年 / 57卷 / 02期
关键词
Metformin; Sulfonylurea compounds; Glucagon-like peptide 1 analogues; Dipeptidyl-peptidase; 4; inhibitors; Sodium-glucose transporter 2 inhibitors; JEJUNAL BYPASS LINER; CARDIOVASCULAR OUTCOMES; BARIATRIC SURGERY; GLYCEMIC CONTROL; METFORMIN; THERAPY; RISK; DAPAGLIFLOZIN; ASSOCIATION; MELLITUS;
D O I
10.1007/s00108-015-0002-x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
New glucose-lowering drugs have raised the complexity of diabetes treatment in recent years. While metformin is still the first choice in monotherapy for most cases, various options exist for dual combination therapy. In addition, combinations of three different oral glucose-lowering drugs are increasingly used. Insulin therapy is typically initiated using once daily administration of a long-acting insulin. If basal insulin alone is no longer sufficient, treatment can be intensified by adding short-acting insulin at mealtime or by combining basal insulin with oral glucose-lowering drugs or a glucagon-like peptide (GLP)-1 analogue. The choice of the most appropriate glucose-lowering drug should take into account not only the glucose-lowering efficacy, but also the side effect profile of the respective agents; economic factors must be considered as well. Modern treatment of type 2 diabetes should aim for near-normal glucose control.
引用
收藏
页码:153 / 165
页数:13
相关论文
共 50 条
  • [31] Approaches to treatment of type 2 diabetes
    Bloomgarden, Zachary T.
    DIABETES CARE, 2008, 31 (08) : 1697 - 1703
  • [32] Treatment of diabetes mellitus type 2
    Matthaei, S.
    Haering, H. U.
    DIABETOLOGIE UND STOFFWECHSEL, 2007, 2 : S173 - S177
  • [33] Lixisenatide in the treatment of Type 2 diabetes
    Donsmark, Morten
    Knudsen, Lotte Bjerre
    EXPERT REVIEW OF ENDOCRINOLOGY & METABOLISM, 2014, 9 (03) : 197 - 199
  • [34] Depression treatment in type 2 diabetes
    Gois, C.
    Carmo, I
    Barbosa, A.
    PSYCHOTHERAPY AND PSYCHOSOMATICS, 2013, 82 : 36 - 36
  • [35] Dulaglutide for the treatment of type 2 diabetes
    Scheen, Andre J.
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2017, 17 (04) : 485 - 496
  • [36] Treatment of type 2 diabetes in the elderly
    Gomez Huelgas, Ricardo
    Diez-Espino, Javier
    Formiga, Francesc
    Lafita Tejedor, Javier
    Rodriguez Manas, Leocadio
    Gonzalez-Sarmiento, Enrique
    Menendez, Edelmiro
    Sangros, Javier
    MEDICINA CLINICA, 2013, 140 (03): : 134 - 134
  • [37] ALOGLIPTIN FOR THE TREATMENT OF TYPE 2 DIABETES
    White, J. R.
    DRUGS OF TODAY, 2011, 47 (02) : 99 - 107
  • [38] LIXISENATIDE FOR THE TREATMENT OF TYPE 2 DIABETES
    Petersen, A. B.
    Knop, F. K.
    Christensen, M.
    DRUGS OF TODAY, 2013, 49 (09) : 537 - 553
  • [39] Treatment issues in type 2 diabetes
    Bloomgarden, ZT
    DIABETES CARE, 2002, 25 (02) : 390 - 394
  • [40] Insulin treatment for type 2 diabetes
    Riddle, MC
    Karl, DM
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1998, 279 (19): : 1523 - 1523